Ichor Medical Systems

Ichor Medical Systems is a private, platform-focused biotechnology company with a long-established expertise in electroporation-based drug delivery. Its core asset is the clinically tested TriGrid Delivery System, which enhances the potency and reproducibility of nucleic acid administration for vaccines and therapeutics. The company has successfully licensed its technology to major pharmaceutical firms like Pfizer and Janssen and has received US government funding, positioning it as an enabler in the growing field of genetic medicine. Ichor's business model is centered on strategic partnerships to commercialize its delivery platform.

TriGrid Delivery System: an integrated, automated electroporation device for enhanced intramuscular delivery of nucleic acids (DNA/RNA). It features a disposable electrode array and single-button activation for consistent, user-independent administration.

Ichor competes in the niche of electroporation-based drug delivery. Key competitors include Inovio Pharmaceuticals (which develops combined device/drug platforms) and other private device firms. Its primary competitive advantage is its fully automated, user-independent device design and strong IP portfolio.